title: Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells.
authors.forename: R
authors.initials: R
authors.lastname: Wehner
authors.forename: M
authors.initials: M
authors.lastname: Wendisch
authors.forename: K
authors.initials: K
authors.lastname: Schäkel
authors.forename: M
authors.initials: M
authors.lastname: Bornhäuser
authors.forename: U
authors.initials: U
authors.lastname: Platzbecker
authors.forename: B
authors.initials: B
authors.lastname: Mohr
authors.forename: A
authors.initials: A
authors.lastname: Temme
authors.forename: M
authors.initials: M
authors.lastname: Bachmann
authors.forename: E P
authors.initials: EP
authors.lastname: Rieber
authors.forename: M
authors.initials: M
authors.lastname: Schmitz
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001549:Benzamides; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology; D005434:Flow Cytometry; D006801:Humans; D000068877:Imatinib Mesylate; D016130:Immunophenotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate